About Cytosorbents Corporation - Common Stock (CTSO)
Cytosorbents Corporation is a medical technology company that focuses on developing innovative therapeutic solutions for critical care and cardiovascular patients. Their flagship product, CytoSorb, is a blood purification device designed to remove cytokines and other harmful substances from the bloodstream during severe illnesses, such as sepsis or acute respiratory distress syndrome. The company is dedicated to advancing treatment options that improve patient outcomes and reduce healthcare costs through its cutting-edge technology, which aims to enhance the management of life-threatening conditions in hospital settings. Read More
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025
PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2024 financial results and recent business highlights after the market close on Thursday, March 6, 2025.
PRINCETON, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates (UAE). The new subsidiary provides a gateway into the Middle East and Africa - regions with increasing demand for advanced medical technologies and high-quality therapies in critical care and cardiac surgery.
